Bernard Thébaud

Senior Scientist, CHEO Research Institute

Dr. Bernard Thébaud is a clinician-scientist recruited to Ottawa from Edmonton in 2012 to accelerate the translation of stem cell-based therapies for lung diseases.His lab studies the mechanisms of lung development, injury and repair in order to design new treatments for incurable lung diseases. The current focus is on stem cell-based and gene therapies. He has set out an ambitious research program in order to study clinically relevant questions for translation into real-life applications. His unique multi-disciplinary program offers the full scope of translational research from (i) discovery research in the petri dish to (ii) manufacturing and preclinical in vitro and in vivo testing of novel cell/gene therapies to (iii) preparing and conducting clinical trials. Over the next five years, his goal is to bring safe and effective cell-based therapies for lung diseases into the clinic, and thereby create vast improvements in patient outcomes. A phase I Trial (HULC-I: Helping Under-developed Lungs with Cells) will be underway in 2020. Dr. Thébaud holds the University of Ottawa Partnership Research Chair in Regenerative Medicine. His research is funded by a CIHR Foundation Scheme grant, the Heart and Stroke Foundation of Canada, theStem Cell Network and the Ontario Institute of Regenerative Medicine.

Research Projects

  1. Characterization of the innate immune response in a novel murine model mimicking bronchopulmonary dysplasia

    01/05/2020

    This is the first report of in-depth characterization of the lung injury and recovery describing the evolution of the innate immune response in a standardized mouse model for experimental BPD with postnatal LPS and hyperoxia exposure.

  2. Are all stem cells equal? Systematic review, evidence map, and meta‐analyses of preclinical stem cell‐based therapies for bronchopulmonary dysplasia

    01/11/2019

    We performed a systematic review and network meta‐analysis (NMA) of preclinical studies testing cell‐based therapies in experimental neonatal lung injury.

  3. Target oxygen saturation and development of pulmonary hypertension and increased pulmonary vascular resistance in preterm infants

    01/01/2019

    Higher targeted oxygen saturation was associated with reduced risk of PH or elevated PVR in extremely preterm infants compared to lower oxygen saturation target.

  4. Existence, Functional Impairment, and Lung Repair Potential of Endothelial Colony-Forming Cells in Oxygen-Induced Arrested Alveolar Growth

    01/05/2014

    We show for the first time that ECFCs exist in the distal vasculature of the developing mammalian lung, and their functional capacity is impaired in oxygen-induced lung damage. We also show that therapeutic supplementation with human umbilical cord blood–derived ECFCs is feasible, efficacious, and apparently safe in this experimental O2-induced model of BPD in neonatal mice.

  5. Airway Delivery of Mesenchymal Stem Cells Prevents Arrested Alveolar Growth in Neonatal Lung Injury in Rats

    01/12/2009

    MSC treatment preserved alveolar structure in a model of chronic lung disease in newborn rats caused by severe hyperoxia, which may be due to a paracrine effect on lung cells. MSCs may have therapeutic potential for preventing neonatal lung diseases characterized by alveolar damage.